AAV2-GDNF for Advanced Parkinson s Disease
- Glial cell line-derived neurotrophic factor (GDNF) is a chemical that may help protect and strengthen brain cells that produce dopamine. Dopamine is a chemical that affects brain function. People with Parkinson's disease (PD) have problems producing dopamine in the brain. Researchers want to see if gene transfer can help deliver GDNF into the area of the brain that is damaged by PD. The gene transferred in this study, called AAV2-GDNF, may help produce GDNF to protect the damaged brain cells.
- To test the safety and effectiveness of AAV2-GDNF gene transfer for advanced PD.
- Individuals at least 18 years of age who have advanced PD that is not well controlled by medications.
- Participants will be in the study for about 5 years. There will be 18 outpatient study visits and a 3-day stay in the hospital. There may also be overnight stays for followup visits.
- Participants will be screened with a physical exam and medical history. Blood samples will be collected. Tests of PD symptoms and mood and memory will be given. Imaging studies will be used to find the right part of the brain to infuse the gene. The screening visit will take place up to 60 days before surgery.
- Participants will have a baseline visit about a month before the surgery. For 1 week before the baseline visit, participants will keep a diary on any motor problems. The visit will involve movement tests given before and after taking a regular dose of levodopa.
- Participants will have surgery to infuse AAV2-GDNF into the brain. The surgery will also include a lumbar puncture (spinal tap) to collect cerebrospinal fluid. After surgery, participants will recover in the hospital for at least 2 days.
- Participants will have another lumbar puncture 6 and 18 months after surgery. This will be an outpatient visit.
- Participants will have regular followup visits after the surgery. These visits will include neurological tests and movement studies. Visits with a neurosurgeon will take place 1, 2, and 4 weeks after surgery. Additional visits will take place every 3 months for the first 3 years, and then at longer intervals for up to 5 years.
|Parkinson's Disease||Genetic: Convection enhanced delivery/AAV2-GDNF||Phase 1|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
|Official Title:||A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects With Advanced Parkinson's Disease|
- Assess the safety and tolerability of 4 different dose levels of AAV2-GDNF [ Time Frame: 12 Years ]
- Obtain preliminary data regarding the potential for clinical responses of the 4 dose levels tested by assessing the magnitude and variability of any treatment effects (via clinical, laboratory and neuroimaging studies). [ Time Frame: 12 Years ]
|Study Start Date:||May 29, 2012|
|Estimated Study Completion Date:||December 31, 2027|
|Estimated Primary Completion Date:||January 1, 2025 (Final data collection date for primary outcome measure)|
While medications can temporarily alleviate the symptoms of Parkinson s disease (PD), they do not influence the degenerative process. Progressive loss of nigral dopaminergic (DA) neurons (the pathological hallmark of PD) results in progressive neurologic dysfunction and death. Glial cell line-derived neurotrophic factor (GDNF) was first identified based on its ability to promote the survival of embryonic DA neurons in vitro, and research has demonstrated beneficial effects of GDNF in animal models of PD. Preliminary clinical trials of GDNF infusions have yielded inconclusive results. Observed problems with tolerability and efficacy in these studies may have been related to the methods of delivery. Recent evidence indicates that gene transfer via direct delivery of viral vectors may represent a superior approach for the treatment of PD with GDNF.
Twenty-four adult male and female subjects with advanced Parkinson s disease, who are candidates for surgical treatment for Parkinson s disease and who meet all Inclusion and Exclusion Criteria.
We propose a Phase 1 single-center, open-label, dose escalation, safety and tolerability study of adeno-associated virus, serotype 2 vector (AAV2) containing human GDNF complementary DNA. Bilateral catheters will be placed surgically through the skull and into the brain and the vector will be delivered by convection-enhanced delivery (CED) to both putamina (450 microliters per hemisphere) of 24 patients with advanced PD. An additional 76 subjects will be allowed for screening failures. Four escalating dose levels will be evaluated in the following dose cohorts (6 patients per cohort): Cohort 1 = 9 x 10(10)vg, Cohort 2 = 3 x 10(11)vg, Cohort 3 = 9 x 10(11)vg and Cohort 4 = 3 x 10(12)vg.
To assess the safety, tolerability, and potential clinical effects of CED of AAV2-GDNF in advanced PD patients, we will use defined clinical evaluations of PD (Unified Parkinson s Disease Rating Scale, Modified Schwab and England Activities of Daily Living scale, Hoehn and Yahr Staging, Lang and Fahn Dyskinesia Rating Scale, On-Off Patient Diary, Quality of Life, Modified Rankin Scale, Adverse Event Log and neurologic examinations), laboratory studies (hematologic, immunologic and chemistry), neuropsychological testing (Mattis Dementia Rating Scale, Beck Depression Inventory II and Parkinson Psychosis Questionnaire) and neuroimaging (magnetic resonance imaging and positron emission tomography).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01621581
|Contact: Sana J Zahir||Not Listed||SNBrecruiting@nih.gov|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 email@example.com|
|Principal Investigator:||John D Heiss, M.D.||National Institute of Neurological Disorders and Stroke (NINDS)|